The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 16, 2021

Study Completion Date

December 16, 2022

Conditions
Pain, Postoperative
Interventions
DRUG

CBD Oral Disintegrating Tablet (ODT)

Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen

OTHER

Placebo ODT

"Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine."

Trial Locations (1)

10016

NYU Langone Health, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Orcosa Inc.

INDUSTRY

lead

NYU Langone Health

OTHER

NCT04672252 - The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy | Biotech Hunter | Biotech Hunter